A Prescription Drug User Fee Act target date of December 10, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics ...
Tia Szczepanski, 29, is a pediatric nurse in the ICU at Albany Medical Center and has not been able to go to work recently. That’s because she has been diagnosed with severe aplastic anemia and now ...
Eltrombopag combined with immunosuppressive therapy in pediatric patients with severe aplastic anemia achieved a 54.9% overall response rate at 26 weeks, with a 71.4% response in relapsed/refractory ...
Aplastic anaemia is a rare, life‐threatening disorder of the bone marrow characterised by pancytopenia and a hypocellular marrow. The primary pathophysiology involves immune-mediated destruction of ...
Ayrmid Ltd. (“Ayrmid” or the “Company”), the parent company of Gamida Cell Inc., a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the U.S. Food and Drug ...
FDA assigns Prescription Drug User Fee Act (PDUFA) target date of December 10, 2025 Ayrmid Ltd. (“Ayrmid” or the “Company”), the parent company of Gamida Cell Inc., a cell therapy pioneer working to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback